Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dalpiciclib + Fulvestrant + Trastuzumab + Pertuzumab in HR+/HER2+ Metastatic Breast Cancer
NCT05574881Phase 2Active, not recruiting
- Sponsor
- Fudan University
- Start
- Sep 2022
- Primary completion
- Jan 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of dalpiciclib in breast cancer, sponsored by Fudan University. Started Sep 2022; status: active, not recruiting.
02
Drugs
dalpiciclib
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT05574881.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05574881.